Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
• Collaborators: Groupe Francais De Pneumo-Cancerologie; University Hospital, Caen
• Treatments: Bevacizumab; Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Malignant, histologically proved, non resectable pleural Mesothelioma

• In case of pleural effusion, a talc pleurodesis, although not recommended, is allowed in accordance with current local practice, at the time of diagnostic thorascopy, with inclusion CT scan performed after pleurodesis.

• ECOG Performance status 0-2

• Mesothelioma with only pleural effusion without uni- or bidimensionally measurable disease will be eligible (adapted RECIST criteria)

• At least 18 years of age, less than 76 years of age

• Radiation therapy of thoracocentis tract (3 x 7Gy) performed before beginning medical study treatment, and the interval between thoracoscopic procedure and radiation will not exceed 28 days

Exclusion Criteria:

• Prior chemotherapy

• Brain metastasis

• History of cerebral vascular accident (CVA) or transient ischemic attack